10x Genomics exhibits a business model increasingly reliant on consumables, which provides recurring revenue and some insulation from instrument sales volatility tied to academic funding cycles. The company’s technology platforms are differentiated and supported by ongoing innovation, but instrumen…
10x Genomics (TXG) Q1 2025: 5% Consumables Growth Offsets 42% Instrument Revenue Decline Amid Funding Uncertainty
10x Genomics navigated a challenging macro environment marked by deteriorating U.S. academic funding with solid consumables demand and strategic cost reductions. The company’s strong product innovation and geographic diversification underpin resilience despite a sharp drop in instrument sales. Quarterly guidance signals cautious optimism as management prioritizes balance sheet strength and operational agility amid ongoing funding volatility.
Summary
- Consumables Demand Resilience: Continued growth in consumables underscores core product traction despite instrument sales headwinds.
- Strategic Cost Discipline: Significant expense reductions and workforce trimming position the company for sustained agility.
- Macro Funding Uncertainty: U.S. academic and government research budget pressures drive cautious outlook and withdrawal of full-year guidance.
Business Overview
10x Genomics is a life science technology company specializing in single-cell and spatial biology solutions. Its integrated platform includes instruments, consumables, and software, enabling researchers and biopharmaceutical companies to analyze biological systems at high resolution and scale. The company’s revenue streams are primarily divided between instrument sales and consumables, with spatial biology products (Visium and Xenium) and Chromium single-cell solutions forming its core segments.
Performance Analysis
In Q1 2025, 10x Genomics reported total revenue of $154.9 million, which includes $16.8 million from a patent litigation settlement. Excluding this settlement revenue, core revenue declined 2% year-over-year to $138.1 million, primarily due to a steep 42% drop in instrument sales to $14.8 million. Chromium instrument revenue fell 25%, and spatial instrument revenue plummeted 49%, reflecting constrained capital expenditures in the academic and government sectors.
Conversely, consumables revenue demonstrated resilience, growing 5% to $115.4 million. Chromium consumables were flat at $84.1 million, while spatial consumables surged 18% to $31.2 million, driven by increasing adoption of the Xenium platform. Geographically, Asia-Pacific showed strong growth of 22%, benefiting from structural improvements and direct sales expansion in Japan and China, offsetting declines in Americas and EMEA regions.
- Margin Improvement Despite Headwinds: Gross margin rose to 68%, supported by higher license and royalty revenue and manufacturing efficiencies, though offset partially by increased inventory reserves.
- Operating Expense Reduction: Operating expenses declined 6% to $144.8 million, aided by a $9.2 million gain from the litigation settlement and lower R&D personnel costs.
- Net Loss Narrowing: Net loss improved to $34.4 million from $59.9 million a year ago, reflecting operational cost control and settlement gains.
Overall, the quarter reflects a bifurcated performance with consumables growth offsetting instrument weakness, underscoring the company’s consumables-driven recurring revenue model. However, the sharp instrument decline signals capital spending pressures tied to external funding uncertainties, which management acknowledges as a principal challenge.
Executive Commentary
"Customer enthusiasm and improving consumables trends reinforce our conviction in our technology and in the potential of Single Cell and Spatial."
Serge Saxonov, CEO and Co-founder
"We have implemented a reduction in both headcount and non-headcount related expenses... These changes will allow us to be a more efficient organization better positioned to navigate today's environment while continuing to invest in our highest priorities."
Adam Tate, Chief Financial Officer
Strategic Positioning
1. Navigating Macro Funding Volatility
Management highlighted significant uncertainty in U.S. academic and government research funding, which accounts for approximately 40 to 50% of revenue. Delays and cuts in NIH grants and other funding sources have created unpredictable purchasing behavior, prompting withdrawal of full-year guidance. The company is adopting quarterly guidance to maintain transparency amid this evolving environment.
2. Focus on Consumables and Platform Utilization
Despite instrument sales headwinds, consumables revenue growth—particularly in spatial biology via Xenium—demonstrates robust platform adoption and increasing usage intensity. The company’s strategy to drive consumable pull-through through product innovation like GEMex Flex and universal on-chip multiplexing aims to deepen customer engagement and volume growth.
3. Geographic Diversification and Growth in Asia-Pacific
Strong performance in Asia-Pacific, with 22% revenue growth, reflects strategic investments in direct sales channels and regional expansions, particularly in China and Japan. This diversification partially offsets declines in Americas and EMEA, illustrating resilience against localized macroeconomic pressures.
4. Cost Reduction and Operational Efficiency
The company executed an 8% workforce reduction alongside cuts in discretionary spending, targeting over $50 million in operating expense savings for 2025. This disciplined cost management supports margin improvement and protects the company’s strong cash position of $427 million, enabling continued investment in innovation.
5. Product Innovation and Roadmap Strength
Recent product launches across Chromium, Visium, and Xenium platforms, including multiomic capabilities and cloud-based analytics, maintain 10x Genomics’ technology leadership. These innovations cater to emerging large-scale and translational research applications, positioning the company well for long-term growth despite near-term headwinds.
Key Considerations
10x Genomics is contending with a complex external environment while leveraging internal strengths and strategic initiatives. Key considerations for investors include:
- Funding Dependency Risk: Nearly half of revenue is tied to U.S. academic and government funding, where ongoing uncertainty limits visibility and impacts capital spending.
- Consumables as Revenue Anchor: Growth and increasing utilization of consumables provide a stable, recurring revenue base that cushions instrument sales volatility.
- Geographic Growth Offsets: Asia-Pacific expansion and direct sales model changes offer important revenue diversification and growth avenues.
- Cost Discipline Enables Flexibility: Expense reductions and workforce resizing enhance financial flexibility to weather macro uncertainty and invest in strategic priorities.
- Product Pipeline Momentum: Continued innovation underpins competitive differentiation and supports adoption in emerging clinical and translational research markets.
Risks
The primary risk remains the unpredictable trajectory of U.S. academic and government research funding, which could further suppress instrument sales and overall revenue growth. Additional risks include geopolitical tensions affecting China sales, potential tariff impacts, and the pace of customer adoption for new technologies. Operational execution risks arise from workforce reductions and the need to sustain innovation momentum amid cost constraints.
Forward Outlook
For Q2 2025, 10x Genomics provided guidance of $138 million to $142 million in revenue, representing approximately 1% sequential growth at the midpoint excluding settlement revenue. Management expects similar trends to Q1, with continued pressure on instrument sales but stable to growing consumables demand.
The company withdrew full-year guidance due to limited visibility on macro funding, signaling a cautious stance with a commitment to update guidance when conditions stabilize. Management emphasized readiness to adjust expenses further if necessary to protect the balance sheet.
Takeaways
10x Genomics’ Q1 results reveal a company balancing robust product demand against a challenging funding landscape. The consumables growth and geographic diversification provide important buffers, while cost controls strengthen financial resilience. However, the sharp instrument revenue decline and macro uncertainty remain key headwinds, warranting close monitoring of funding developments and customer purchasing behavior in coming quarters.
- Revenue Mix Shift: The widening gap between consumables growth and instrument decline underscores the evolving business model toward recurring revenue streams, a critical factor for valuation and stability.
- Strategic Agility: Management’s swift cost reductions and sales reorganization reflect proactive steps to align operations with market realities, preserving runway for innovation and growth.
- Visibility and Guidance: The move to quarterly guidance highlights the unpredictable external environment, emphasizing the importance of near-term execution and real-time market assessment.
Conclusion
10x Genomics delivered a mixed Q1 performance marked by resilient consumables growth and significant instrument revenue contraction amid macro funding challenges. The company’s strategic cost management, product innovation, and geographic diversification support confidence in its long-term growth trajectory, though near-term uncertainty necessitates cautious investor vigilance.
Industry Read-Through
The quarter’s results illustrate broader industry dynamics where life science technology companies face funding uncertainties impacting capital equipment sales but benefit from growing consumable and service revenues. The shift toward multiomic and large-scale spatial biology applications signals expanding market opportunities. Other players in single-cell and spatial biology sectors should watch how funding volatility, product innovation, and geographic diversification shape competitive positioning and financial resilience in 2025.